MX337775B - Composiciones de bepotastina. - Google Patents

Composiciones de bepotastina.

Info

Publication number
MX337775B
MX337775B MX2013007409A MX2013007409A MX337775B MX 337775 B MX337775 B MX 337775B MX 2013007409 A MX2013007409 A MX 2013007409A MX 2013007409 A MX2013007409 A MX 2013007409A MX 337775 B MX337775 B MX 337775B
Authority
MX
Mexico
Prior art keywords
compositions including
bepotastine
compositions
bepotastine compositions
corticosteroid
Prior art date
Application number
MX2013007409A
Other languages
English (en)
Other versions
MX2013007409A (es
Inventor
Angel Padilla
George Baklayan
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of MX2013007409A publication Critical patent/MX2013007409A/es
Publication of MX337775B publication Critical patent/MX337775B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona composiciones novedosas que incluyen besilato de bepotastina y un corticoesteroide, composiciones que incluyen al menos aproximadamente 0.008 % p/v de cloruro de benzalconio, y composiciones que incluyen hidroxipropilmetil celulosa E15 LV.
MX2013007409A 2011-01-04 2012-01-03 Composiciones de bepotastina. MX337775B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161429721P 2011-01-04 2011-01-04
PCT/US2012/020028 WO2012094283A2 (en) 2011-01-04 2012-01-03 Bepotastine compositions

Publications (2)

Publication Number Publication Date
MX2013007409A MX2013007409A (es) 2013-11-01
MX337775B true MX337775B (es) 2016-03-18

Family

ID=46457931

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007409A MX337775B (es) 2011-01-04 2012-01-03 Composiciones de bepotastina.

Country Status (12)

Country Link
US (2) US20120323178A1 (es)
EP (1) EP2736491B1 (es)
JP (1) JP5683719B2 (es)
KR (1) KR101546596B1 (es)
CN (1) CN103269687B (es)
AU (1) AU2012204557B2 (es)
BR (1) BR112013017183A2 (es)
CA (1) CA2822683C (es)
ES (1) ES2626134T3 (es)
MX (1) MX337775B (es)
PL (1) PL2736491T3 (es)
WO (1) WO2012094283A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2624836T3 (pl) * 2010-10-06 2016-04-29 Mitsubishi Tanabe Pharma Corp Kompozycje bepotastyny
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
PT3517541T (pt) 2012-05-08 2020-08-28 Nicox Ophthalmics Inc Forma polimórfica de propionato de fluticasona
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
RU2015145449A (ru) * 2013-03-26 2017-05-03 Оптиноуз Ас Интраназальное введение
RS62383B1 (sr) * 2013-09-13 2021-10-29 Glenmark Specialty Sa Stabilna farmaceutska kompozicija sa fiksnom dozom koja sadrži mometazon i olopatadin za nazalnu primenu
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
UA120587C2 (uk) 2013-10-04 2020-01-10 Гленмарк Спешіалті С.А. Спосіб лікування алергічного риніту з використанням комбінації мометазону та олопатадину
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
CN103816121B (zh) * 2014-03-07 2016-01-20 上海现代药物制剂工程研究中心有限公司 苯磺酸贝他斯汀鼻腔喷雾剂及其制备方法
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
JP6945614B2 (ja) * 2014-03-26 2021-10-06 オプティノーズ アズ 経鼻投与
WO2015183047A1 (ko) * 2014-05-30 2015-12-03 동아에스티 주식회사 베포타스틴과 글리세릴베헤네이트를 포함하는 약제학적 제제
US10722510B2 (en) 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
US9980975B2 (en) 2015-01-22 2018-05-29 Ems S.A. Dosage forms containing fluticasone propionate for the treatment of inflammatory conditions of the esophagus
US20170189352A1 (en) 2015-03-13 2017-07-06 Par Pharmaceutical, Inc. Epinephrine formulations
US9119876B1 (en) 2015-03-13 2015-09-01 Par Pharmaceutical, Inc. Epinephrine formulations
JP7106852B2 (ja) * 2016-12-20 2022-07-27 大正製薬株式会社 懸濁型外用液剤
AU2018325461B2 (en) * 2017-09-02 2020-06-11 Iview Therapeutics, Inc. In situ gel-forming pharmaceutical compositions and uses thereof for sinus diseases
EP3755375B1 (en) * 2018-02-23 2025-03-05 Glenmark Specialty S.A. Treatment of allergic rhinitis in pediatric subjects using a combination of mometasone and olopatadine
WO2019183416A1 (en) 2018-03-23 2019-09-26 Nevakar Inc. Epinephrine compositions and containers
US12303635B2 (en) 2018-04-16 2025-05-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
US12102645B2 (en) 2018-06-08 2024-10-01 Toko Yakuhin Kogyo Co., Ltd. Fluticasone furoate nasal preparation composition
EP3725298A1 (en) 2019-04-16 2020-10-21 Faes Farma, S.A. Stable and preserved pharmaceutical compositions of bilastine
US20210283074A1 (en) * 2020-03-16 2021-09-16 Nasus Pharma Ltd. Polymeric Compositions for Intranasal Administration
JP2023547040A (ja) * 2020-09-24 2023-11-09 エヌフレクション セラピューティクス インコーポレイテッド ピロロピリジン－アニリン化合物による、認知機能不全の処置方法
CN117954002B (zh) * 2024-01-05 2024-10-22 苏州腾迈医药科技有限公司 分子对关系的展示方法及装置、介质

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8902300D0 (en) 1989-02-02 1989-03-22 Bryce Smith Derek Antirhinoviral preparations
CN1222852A (zh) * 1996-06-04 1999-07-14 普罗克特和甘保尔公司 含鼻内类固醇和抗组胺剂的鼻喷雾剂
EP0954318A1 (en) * 1996-06-04 1999-11-10 The Procter & Gamble Company A nasal spray containing an intranasal steroid and an antihistamine
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
TW486475B (en) 1996-12-26 2002-05-11 Ube Industries Acid addition salt of optically active piperidine compound and process for preparing the same
GB9918559D0 (en) * 1999-08-07 1999-10-06 Glaxo Wellcome Kk Novel pharmaceutical formulation
DE19947234A1 (de) * 1999-09-30 2001-04-05 Asta Medica Ag Neue Kombination von Loteprednol und Antihistaminika
US6565832B1 (en) * 2000-01-31 2003-05-20 Schering-Plough Healthcare Products, Inc. Spray composition with reduced dripping
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
CA2448627A1 (en) * 2001-05-31 2002-12-05 Pharmacia Corporation Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol
CA2468749A1 (en) * 2001-12-05 2003-06-19 Alcon, Inc. Use of an h1 antagonist and a safe steroid to treat rhinitis
WO2003101434A2 (en) * 2001-12-21 2003-12-11 Sampad Bhattacharya Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor
ATE528003T1 (de) * 2002-07-31 2011-10-15 Senju Pharma Co Wässrige, flüssigkeitszubereitungen und lichtstabilisierte wässrige flüssigkeitszubereitungen
ATE472329T1 (de) * 2002-08-30 2010-07-15 Nycomed Gmbh Verwendung der kombination von ciclesonid und antihistaminika zur behandlung von allergischer rhinitis
US20050112199A1 (en) * 2003-09-24 2005-05-26 Mahesh Padval Therapeutic regimens for administering drug combinations
EP1675550A4 (en) * 2003-09-24 2007-10-10 Combinatorx Inc THERAPEUTIC DOSAGE DIAGRAMS FOR ADMINISTRATION OF MEDICINAL COMBINATIONS
US7405275B2 (en) * 2003-09-24 2008-07-29 Millennium Pharmaceuticals, Inc. Antibodies which bind human CXCR3
EP2522365B1 (en) * 2004-11-24 2016-10-26 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
CN101257891A (zh) * 2005-09-01 2008-09-03 比奥里波克斯公司 包含抗组胺剂以及皮质类固醇的脂质体组合物及其在制备治疗鼻炎以及相关疾病的药物中的用途
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
EP2083798A1 (en) * 2006-10-19 2009-08-05 Cipla Limited Pharmaceutical compositions and nasal spray incorporating anhydrous mometasone furoate
KR100878698B1 (ko) 2007-04-05 2009-01-13 한미약품 주식회사 결정형의 베포타스틴 금속염 수화물, 이의 제조방법 및이를 포함하는 약학 조성물
MX2009010946A (es) 2007-04-11 2009-10-29 Alcon Res Ltd Uso de un inhibidor del factor de necrosis tumoral alfa mas una antihistamina para tratar rinitis alergica y conjuntivitis alergica.
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
KR20090061972A (ko) 2007-12-12 2009-06-17 한미약품 주식회사 베포타스틴 ｐ-톨루엔술폰산염의 결정형, 이의 제조방법 및이를 포함하는 약학 조성물
WO2010026129A1 (en) * 2008-09-02 2010-03-11 Glaxo Group Limited The trpvl antagonist sb-705498 for treating rhinitis
JP2010195716A (ja) 2009-02-25 2010-09-09 Takeda Chem Ind Ltd 点鼻睡眠導入剤
PL2624836T3 (pl) * 2010-10-06 2016-04-29 Mitsubishi Tanabe Pharma Corp Kompozycje bepotastyny

Also Published As

Publication number Publication date
US20120255544A1 (en) 2012-10-11
US10736841B2 (en) 2020-08-11
EP2736491A2 (en) 2014-06-04
AU2012204557A1 (en) 2013-05-02
ES2626134T3 (es) 2017-07-24
CN103269687A (zh) 2013-08-28
US20120323178A1 (en) 2012-12-20
CA2822683C (en) 2015-05-12
CN103269687B (zh) 2016-09-14
EP2736491A4 (en) 2014-07-09
KR20130135296A (ko) 2013-12-10
KR101546596B1 (ko) 2015-08-21
WO2012094283A2 (en) 2012-07-12
JP2014501779A (ja) 2014-01-23
WO2012094283A3 (en) 2012-10-26
MX2013007409A (es) 2013-11-01
BR112013017183A2 (pt) 2017-07-25
CA2822683A1 (en) 2012-07-12
AU2012204557B2 (en) 2015-05-14
JP5683719B2 (ja) 2015-03-11
EP2736491B1 (en) 2017-04-05
PL2736491T3 (pl) 2017-09-29

Similar Documents

Publication Publication Date Title
MX337775B (es) Composiciones de bepotastina.
MX341109B (es) Composiciones de bepotastina.
IN2015DN01480A (es)
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
MX2013012542A (es) Compuestos de amida y aplicacion farmaceutica para el mismo.
ECSP14011359A (es) Inhibidores de bromodominios
MX361499B (es) Baricitinib deuterado.
MX2014004245A (es) Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor xia.
IL232914A0 (en) New Azetidine histories, pharmaceutical preparations and their uses
MX2015001246A (es) Ibrutinib deuterado.
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
MY194495A (en) Compositions and methods for transmucosal absorption
GB201101517D0 (en) Receptor antagonists
MX363843B (es) Composiciones farmaceuticas que comprenden donadores de nitroxilo.
AU2013225816A8 (en) Compositions and methods for treating Type III Gaucher Disease
IN2014DN06869A (es)
MX2016013431A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
MY162886A (en) Novel tetrahydropyridopyrimidine compound or salt thereof
IN2014DN09347A (es)
GEP201706739B (en) Compositions comprising vortioxetine and donepezil
MX2010004487A (es) Derivados lactamicos sustituidos y sus usos para glaucoma e hipertension ocular.
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MX2010005105A (es) Ciclopentanos substituidos que comprenden actividad de prostaglandina.
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).

Legal Events

Date Code Title Description
FG Grant or registration